



Xencor, Inc.
Investor Relations Department
111 West Lemon Avenue
Monrovia, CA 91016
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: XNCR

Last Trade:	20.98
Trade Time:	4:00 PM ET Aug 16, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	18.45 - 29.38
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since Xencor's founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. Currently, 11 candidates that have been engineered with Xencor's XmAb® technology are in clinical development by us or with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1a development fo... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 7, 2017*
[Xencor Reports Second Quarter 2017 Financial Results](#)
- Aug 2, 2017*
[Xencor to Present at Upcoming Investor Conferences](#)
- Jul 31, 2017*
[Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017](#)
- Jun 16, 2017*
[Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017](#)
- Jun 8, 2017*
[Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 7, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016*
[Quarterly Report \(10-Q\)](#)